| Sonoma Pharmaceuticals: 150.000 Aktien gekauft - das ist der Grund! | Die Aktie von Sonoma Pharmaceuticals ist Zockern aus der sharedeals.de-Community seit Jahren bekannt. Mehrfach wurden dreistellige Kurs-Peaks innerhalb kürzester Zeit für herausragend lukrative Trading-Exits... ► Artikel lesen |
| Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering | BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology... ► Artikel lesen |
| Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart | BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders | Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Compliant with Nasdaq Bid Price Rule | JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Reports First Quarter 2026 Financials | Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi and Canalevia-CA1Company continues its focus on crofelemer... ► Artikel lesen |